Pfizer Inc. and Astellas Pharma Inc. reported positive topline results from the Phase 3 EV-303 (KEYNOTE-905) clinical trial. The study evaluated PADCEV™ (enfortumab vedotin), a Nectin-4-directed antibody-drug conjugate, in combination with KEYTRUDA™ (pembrolizumab), a PD-1 inhibitor, as neoadjuvant and adjuvant treatment compared with surgery alone in patients with muscle-invasive bladder cancer (MIBC) who were ineligible … New Combo Therapy Shows Major Survival Gains in Cisplatin-Ineligible Bladder Cancer Read More » To access this post, you must purchase Individual Subscriber Yearly or Enterprise Subscriber.